227 related articles for article (PubMed ID: 30885362)
1. Pharmacology of ME-344, a novel cytotoxic isoflavone.
Zhang L; Zhang J; Ye Z; Townsend DM; Tew KD
Adv Cancer Res; 2019; 142():187-207. PubMed ID: 30885362
[TBL] [Abstract][Full Text] [Related]
2. Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1.
Zhang L; Zhang J; Ye Z; Manevich Y; Ball LE; Bethard JR; Jiang YL; Broome AM; Dalton AC; Wang GY; Townsend DM; Tew KD
Cancer Res; 2019 Aug; 79(16):4072-4085. PubMed ID: 31227482
[TBL] [Abstract][Full Text] [Related]
3. Voltage-Dependent Anion Channels Influence Cytotoxicity of ME-344, a Therapeutic Isoflavone.
Zhang L; Townsend DM; Morris M; Maldonado EN; Jiang YL; Broome AM; Bethard JR; Ball LE; Tew KD
J Pharmacol Exp Ther; 2020 Aug; 374(2):308-318. PubMed ID: 32546528
[TBL] [Abstract][Full Text] [Related]
4. Phenoxodiol: isoflavone analog with antineoplastic activity.
Choueiri TK; Wesolowski R; Mekhail TM
Curr Oncol Rep; 2006 Mar; 8(2):104-7. PubMed ID: 16507219
[TBL] [Abstract][Full Text] [Related]
5. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs.
Silasi DA; Alvero AB; Rutherford TJ; Brown D; Mor G
Expert Opin Pharmacother; 2009 Apr; 10(6):1059-67. PubMed ID: 19364253
[TBL] [Abstract][Full Text] [Related]
6. Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344.
Manevich Y; Reyes L; Britten CD; Townsend DM; Tew KD
J Pharmacol Exp Ther; 2016 Aug; 358(2):199-208. PubMed ID: 27255112
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of phenoxodiol: from bench to clinic.
Alvero AB; Kelly M; Rossi P; Leiser A; Brown D; Rutherford T; Mor G
Future Oncol; 2008 Aug; 4(4):475-82. PubMed ID: 18684059
[TBL] [Abstract][Full Text] [Related]
8. A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia.
Jeyaraju DV; Hurren R; Wang X; MacLean N; Gronda M; Shamas-Din A; Minden MD; Giaever G; Schimmer AD
Oncotarget; 2016 Aug; 7(31):49777-49785. PubMed ID: 27391350
[TBL] [Abstract][Full Text] [Related]
9. Phenoxodiol, a novel approach for the treatment of ovarian cancer.
Mor G; Fu HH; Alvero AB
Curr Opin Investig Drugs; 2006 Jun; 7(6):542-8. PubMed ID: 16784025
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of isoflavones and biflavonoids from Ormocarpum kirkii towards multi-factorial drug resistant cancer.
Adem FA; Mbaveng AT; Kuete V; Heydenreich M; Ndakala A; Irungu B; Yenesew A; Efferth T
Phytomedicine; 2019 May; 58():152853. PubMed ID: 30836216
[TBL] [Abstract][Full Text] [Related]
11. Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway.
Li Y; Huang X; Huang Z; Feng J
Cell Biochem Biophys; 2014 Nov; 70(2):1337-42. PubMed ID: 24902539
[TBL] [Abstract][Full Text] [Related]
12. The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth.
Bellou S; Karali E; Bagli E; Al-Maharik N; Morbidelli L; Ziche M; Adlercreutz H; Murphy C; Fotsis T
Mol Cancer; 2012 May; 11():35. PubMed ID: 22583931
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer.
de Souza PL; Russell PJ; Kearsley JH; Howes LG
Nutr Rev; 2010 Sep; 68(9):542-55. PubMed ID: 20796219
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Therapeutic Potential of Phenoxodiol, a Novel Isoflavone Analog, in Renal Cancer Cells.
Isono M; Sato A; Asano T; Okubo K; Asano T
Anticancer Res; 2018 Oct; 38(10):5709-5716. PubMed ID: 30275191
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anti-tumor activities of novel oxazinyl isoflavonoids.
Wang D; Hou L; Wu L; Yu X
Chem Pharm Bull (Tokyo); 2012; 60(4):513-20. PubMed ID: 22466735
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of tubulin-barbigerone complex enables rational design of potent anticancer agents with isoflavone skeleton.
Yan W; Li Y; Liu Y; Wen Y; Pei H; Yang J; Chen L
Phytomedicine; 2023 Jan; 109():154550. PubMed ID: 36610121
[TBL] [Abstract][Full Text] [Related]
17. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1.
Aguero MF; Facchinetti MM; Sheleg Z; Senderowicz AM
Cancer Res; 2005 Apr; 65(8):3364-73. PubMed ID: 15833870
[TBL] [Abstract][Full Text] [Related]
18. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
19. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.
Kluger HM; McCarthy MM; Alvero AB; Sznol M; Ariyan S; Camp RL; Rimm DL; Mor G
J Transl Med; 2007 Jan; 5():6. PubMed ID: 17257402
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic flavonoids from two
Adem FA; Kuete V; Mbaveng AT; Heydenreich M; Koch A; Ndakala A; Irungu B; Yenesew A; Efferth T
Nat Prod Res; 2019 Sep; 33(18):2609-2617. PubMed ID: 29656660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
